Our results indicate that VEGFR2 inhibitors to prevent vascular action and immune cell translocation could be a new additional therapeutic strategy for rheumatoid arthritis patients as an adjunct to existing disease-modifying therapies. Here, KDR is linked to rheumatoid arthritis.